Hims & Hers Pivots to Branded GLP-1s and Strikes Eucalyptus Deal Amid Q1 Margin Pressure
As regulatory pressure on compounded GLP-1 medications tightens, Hims & Hers is shifting its weight-loss strategy toward branded pharmaceutical partnerships — including with Novo — and striking a deal with Eucalyptus to establish an international presence, even as Q1 2026 results revealed a $92 million net loss and raised scrutiny over margins.
INDUSTRY
Editor
5/19/20262 min read
Hims & Hers Health (NYSE: HIMS) is reshaping its growth strategy, pivoting away from compounded GLP-1 weight-loss medications toward branded partnerships with pharmaceutical companies including Novo, while simultaneously striking a deal with Eucalyptus — the Australian digital health platform — to expand its international footprint. The announcements emerged alongside the company's Q1 2026 financial results, reported in mid-May 2026, which showed continued top-line growth offset by significant margin compression and a widened net loss.
Hims & Hers operates a direct-to-consumer digital health platform serving a broad range of conditions primarily affecting men, including erectile dysfunction, hair loss, and weight management. The company built a substantial GLP-1 weight-loss business on the back of access to compounded versions of popular medications — a model that allowed it to undercut traditional pharmaceutical pricing and reach consumers directly. However, regulatory scrutiny from the FDA has tightened the window for compounding, and the company has begun transitioning to agreements with branded drug manufacturers. The Eucalyptus deal extends this strategy internationally: Eucalyptus operates leading direct-to-consumer health platforms in Australia and international markets, with notable men's health products under its portfolio.
Q1 2026 results showed revenue of $608 million and a net loss of $92 million. The company raised its full-year 2026 guidance and reaffirmed its 2030 revenue and EBITDA targets, with management characterising the Q1 results as broadly misunderstood by the market. HIMS shares declined approximately 14.3% in the days following the earnings release. The company holds a market capitalisation of approximately $5.74 billion as of mid-May 2026.
The significance of the Eucalyptus deal and the GLP-1 brand pivot extends beyond near-term financial results. Compounded GLP-1 drugs provided Hims & Hers with a short-term pricing and access edge, but that model carried inherent regulatory risk. By building commercial relationships with brand-name manufacturers and acquiring distribution reach via Eucalyptus's established telehealth infrastructure, Hims & Hers is constructing a more defensible, scalable growth model — one that relies on platform scale and consumer trust rather than regulatory arbitrage. For the broader men's health telehealth market, the pivot signals that the next competitive phase of GLP-1 weight management will be won through branded partnerships and international reach, not compounding.